Tuberculous chorioretinitis
ICD-10 A18.53 is a billable code used to indicate a diagnosis of tuberculous chorioretinitis.
Tuberculous chorioretinitis is an ocular manifestation of tuberculosis (TB) that affects the choroid and retina of the eye. It is characterized by inflammation caused by the Mycobacterium tuberculosis bacteria, which can spread to the eye from a primary pulmonary infection or through hematogenous dissemination. Clinically, patients may present with symptoms such as blurred vision, floaters, and photophobia. Diagnosis typically involves a combination of clinical examination, imaging studies like fluorescein angiography, and laboratory tests including tuberculin skin tests or interferon-gamma release assays. Treatment usually consists of antitubercular therapy, which may include a combination of isoniazid, rifampicin, ethambutol, and pyrazinamide, tailored to the patient's specific needs and drug susceptibility patterns. Monitoring for potential drug resistance is crucial, as multidrug-resistant TB can complicate treatment. Public health implications are significant, as TB is a contagious disease, necessitating contact tracing and isolation procedures for active cases to prevent further transmission.
Detailed ocular examination findings, imaging results, and treatment plans.
Patients presenting with vision changes, floaters, or signs of inflammation in the eye.
Need for collaboration with infectious disease specialists for comprehensive management.
Complete medical history, including TB exposure, diagnostic test results, and treatment response.
Patients with confirmed TB who develop ocular symptoms.
Monitoring for drug resistance and adherence to treatment protocols.
Used when a patient with tuberculous chorioretinitis is evaluated for vision changes.
Complete ocular examination findings and any relevant history of TB.
Ophthalmologists should document the relationship between TB and ocular findings.
Common symptoms include blurred vision, floaters, and photophobia. Patients may also experience vision loss in severe cases.
Diagnosis typically involves a combination of clinical examination, imaging studies like fluorescein angiography, and laboratory tests confirming TB infection.
Treatment usually involves a multi-drug regimen of antitubercular medications, tailored to the patient's specific needs and drug susceptibility.
